X

Trial Profile

Phase 1b study of U3-1287 in combination with trastuzumab plus paclitaxel in patients with HER2-positive metastatic breast cancer (MBC)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Patritumab (Primary) ; Paclitaxel; Trastuzumab
Indications Advanced breast cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Daiichi Sankyo Company

Most Recent Events

12 Jun 2018 Status changed from active, no longer recruiting to completed.
19 Jul 2017 Planned End Date changed from 30 Nov 2016 to 31 Dec 2018.
13 Jun 2016 Planned End Date changed from 30 Nov 2015 to 30 Nov 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com